Hormonal
Glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide) produce statistically significant weight loss in overweight or obese patients with type 2 diabetes compared to placebo, with no significant difference in efficacy between the different GLP-1 agonists or dosages.
If you have Type 2 Diabetes and are overweight, GLP-1 receptor agonist medications (like Exenatide or Liraglutide) are clinically proven to help you lose weight compared to a placebo. The amount of weight loss is modest (around 1-1.6 kg over 6 months) but consistent across different types of these drugs. This is significant because even small weight losses can improve survival and health outcomes in diabetes. These medications are injectable and may cause temporary stomach issues, but they are more effective for weight loss than many other common diabetes drugs that cause weight gain.
This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.
Why this rating
High-quality systematic review and mixed treatment comparison meta-analysis of 27 randomized controlled trials, though some heterogeneity and publication bias were noted.
Source
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Jessica Potts et al. · PLoS ONE · 2015
DOI 10.1371/journal.pone.0126769
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →